Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations

Blood

Volumn 101, Issue 7, 2003, Pages 2797-2803

  Karlsson, Åsa ^b   Giuriato, Sylvie ^b   Tang, Flora ^b   Fung Weier, Jingly ^b   Levan, Göran ^b   Felsher, Dean W ^a  

^a STANFORD UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GENETICS; CANCER RECURRENCE; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; GENE INACTIVATION; GENE OVEREXPRESSION; GENOME; HEMATOPOIETIC SYSTEM TUMOR; KARYOTYPING; LYMPHOMA; MOUSE; NONHUMAN; ONCOGENE MYC; PRIORITY JOURNAL; REVERTANT; SPECTROSCOPY; TUMOR REGRESSION; ANIMAL; CELL CULTURE; CELL TRANSFORMATION; CHROMOSOME ANALYSIS; DRUG EFFECT; GENE SILENCING; GENE TRANSLOCATION; GENETICS; RECURRENT DISEASE; TREATMENT OUTCOME;

DOXYCYCLINE;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CYTOGENETIC ANALYSIS; DOXYCYCLINE; GENE SILENCING; GENES, MYC; LYMPHOMA; MICE; RECURRENCE; TRANSLOCATION, GENETIC; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 0038107350     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-10-3091     Document Type: Article

References (27)

1. Bishop JM. Molecular themes in oncogenesis. Cell. 1991;64:235-248.
2. Grandori C, Cowley SM, James LP, Elsenman RN. The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol. 2000;16:653-699.
3. Hecht JL, Aster JC. Molecular biology of Burkitt's lymphoma. J Clin Oncol. 2000;18:3707-3721.
4. Oster SK, Ho CS, Soucie EL, Penn LZ. The myc oncogene: MarvelouslY Complex. Adv Cancer Res. 2002;84:81-154.
5. Boxer LM, Dang CV. Translocations involving c-myc and c-myc function. Oncogene. 2001;20:5595-5610.
6. Land H, Chen AC, Morgenstern JP, Parada LF, Weinberg RA. Behavior of myc and ras oncogenes in transformation of rat embryo fibroblasts. Mol Cell Biol. 1986;6:1917-1925.
7. Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cel/survival and cooperates with c-myc to immortalize pre-B cells. Nature. 1988;335:440-442.
8. Haupt Y, Bath ML, Harris AW, Adams JM. bmi-1 transgene induces lymphomas and collaborates with myc in tumorigenesis. Oncogene. 1993;8:3161-3164.
9. van Lohuizen M, Verbeek S, Krimpenfort P, et al. Predisposition to lymphomagenesis in pim-1 transgenic mice: cooperation with c-myc and N-myc in murine leukemia virus-induced tumors. Cell. 1989;56:673-682.
10. Allen JD, Verhoeven E, Domen J, van der Vatk M, Berns A. Pim-2 transgene induces lymphoid tumors, exhibiting potent synergy with c-myc. Oncogene. 1997;15:1133-1141.
11. Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev. 1999;13:2658-2669.
12. Liyanage M, Coleman A, du Manoir S, et al. Multi-colour spectral karyotyping of mouse chromosomes. Nat Genet. 1996;14:312-315.
13. Rao PH, Cigudosa JC, Ning Y, et al. Multicolor spectral karyotyping identifies new recurring breakpoints and translocations in multiple myeloma. Blood. 1998;92:1743-1748.
14. McCormack SJ, Weaver Z, Deming S, et al. Myc/p53 interactions in transgenic mouse mammary development, tumorigenesis and chromosomal instability. Oncogene. 1998;16:2755-2766.
15. Coleman AE, Ried T, Janz S. Chromosomes 1 and 5 harbor plasmacytoma progressor genes in mice. Genes Chrom Cancer. 2000;29:170-174.
16. Felsher DW, Bishop JM. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell. 1999;4:199-207.
17. Chin L, Tam A, Pomerantz J, et al. Essential role for oncogenic Ras in tumour maintenance. Nature. 1999;400:468-472.
18. Fisher GH, Wellen SL, Klimstra D, et al. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev. 2001;15:3249-3262.
19. Huettner CS, Zhang P, Van Etten RA, Tenen DG. Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat Genet. 2000;24:57-60.
20. Jain M, Arvanitis C, Chu K, et al. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science. 2002;297:102-104.
21. Pelengaris S, Khan M, Evan GI. Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell. 2002;109:321-334.
22. Weinstein IB. Addiction to oncogenes - the Achilles heal of cancer. Science. 2002;297:63-64.
23. Schmitt CA, Fridman JS, Yang M, Baranov E, Hoffman RM, Lowe SW. Dissecting p53 tumor suppressor functions in vivo. Cancer Cell. 2002;1:289-298.
24. Felsher DW, Bishop JM. Transient excess of MYC activity can elicit genomic instability and tumorigenesis. Proc Natl Acad Sci U S A. 1999;96:3940-3944.
25. Artandi SE, DePinho RA. Mice without telomerase: what can they teach us about human cancer? Nat Med. 2000;6:852-855.
26. Reddy KS, Murphy T. Fusion of 9 beta-satellite and telomere (TTAGGG)n sequences results in a jumping translocation. Human Genet. 2000;107:268-275.
27. Mitelman F, Mertens F, Johansson B. A break-point map of recurrent chromosomal rearrangements in human neoplasia. Nat Genet. 1997;Spec No:417-474.